Visão geral da empresa
A clinical-stage biopharmaceutical enterprise, Genelux Corporation concentrates its operational resources on the creation of oncolytic viral immunotherapies tailored for patients affected by aggressive or difficult-to-treat solid tumor types. Operating within the Healthcare sector and specifically the Biotechnology industry, the company leverages proprietary modified strains to target specific cancer cell populations while sparing healthy tissue. The total market capitalization stands at $114.70M, while the annual revenue for the trailing twelve months is recorded at $8,000, supported by a workforce of 25 employees. These financial figures indicate a highly specialized micro-cap entity where revenue generation is currently minimal relative to the substantial market valuation, suggesting the firm is prioritizing research and development expenditures over immediate commercial scalability.
Saúde financeira
For the trailing twelve months, Genelux reported a revenue of $8,000 alongside a net income of $-32,145,000 and an EBITDA of $-32,970,000, revealing a significant structural gap where operating expenses far exceed the negligible income generated. The company's free cash flow stands at $-14,364,750, indicating that cash outflows for capital expenditures and working capital exceed the limited cash inflows from operations, which constrains immediate financial flexibility. The gross margin is reported at 100.0%, which typically reflects direct cost of goods sold being negligible or zero in early-stage biotechnology, yet the operating margin plunges to -117650.0%, signaling that overhead costs, such as R&D and administrative expenses, are vastly disproportionate to current sales. Consequently, the profit margin is 0.0%, confirming that the company is not generating any net profit from its sales activities. On the balance sheet, cash reserves of $14.60M provide a buffer against total debt of $1.69M, though the debt-to-equity ratio of 14.60 suggests a leveraged position relative to shareholder equity. The current ratio of 2.43 indicates that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin. However, the return on equity of -170.0% and the return on assets of -77.3% demonstrate that the management team is currently destroying value per unit of capital employed rather than generating returns.
Avaliação de valorização
The trailing twelve-month P/E ratio is N/A due to the negative earnings, while the forward P/E is calculated at -3.11, a metric that implies the market is pricing in expectations of future profitability rather than current earnings performance. The price-to-book ratio sits at 8.37, indicating that the market values the company at a significant premium of 8.37 times its tangible book value, reflecting high expectations for the potential success of its lead product candidate despite current losses. Alternative valuation metrics show a price-to-sales ratio of 14337.86 and an EV/EBITDA of -3.05, figures that suggest the market is valuing the entity based on its asset potential and future drug approval prospects rather than historical sales efficiency. The stock has traded between a 52-week high of $8.54 and a 52-week low of $1.99, establishing a wide volatility range where the current market price must be contextualized against these extremes to understand investor sentiment. The beta coefficient is 0.46, which implies that the stock price exhibits lower volatility relative to the broader market benchmark, moving with less intensity than the overall index during periods of market fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between sales and profitability in the current reporting period. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically retained for reinvestment into research and development rather than distributed to shareholders. The absence of a dividend policy is consistent with the company's lifecycle stage, where capital is directed toward advancing clinical trials for Olvi-Vec rather than rewarding investors with cash distributions. The overall growth and income profile is characterized by a lack of historical growth data and zero dividend income, relying entirely on the potential for future commercialization to drive value creation.